Efficacy of DNK333 in Patients With COPD and Cough

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

This study evaluates the efficacy and safety of two weeks treatment of DNK333 in patients with COPD and cough.

Phase 1/Phase 2

Novartis